Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.

Autor: Huang HJ; Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA., Yi SG; Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA., Mobley CM; Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA., Saharia A; Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA., Bhimaraj A; Department of Cardiology, Houston Methodist Hospital, Houston, Texas, USA., Moore LW; Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA.; Center for Outcomes Research, Houston Methodist Hospital, Houston, Texas, USA., Kloc M; Transplant Immunobiology, Houston Methodist Hospital, Houston, Texas, USA., Adrogue HE; Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA., Graviss EA; Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA.; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA., Nguyen DT; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA., Eagar TN; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA., Jones SL; Center for Outcomes Research, Houston Methodist Hospital, Houston, Texas, USA., Ankoma-Sey V; Liver Associates of Texas, Houston, Texas, USA., MacGillivray TE; Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, Texas, USA., Knight RJ; Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA., Gaber AO; Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA., Ghobrial RM; Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: Clinical transplantation [Clin Transplant] 2022 May; Vol. 36 (5), pp. e14600. Date of Electronic Publication: 2022 Feb 02.
DOI: 10.1111/ctr.14600
Abstrakt: Response to two doses of a nucleoside-modified messenger ribonucleic acid (mRNA) vaccine was evaluated in a large solid-organ transplant program. mRNA COVID-19 vaccine was administered to transplant candidates and recipients who met study inclusion criteria. Qualitative anti-SARS-CoV-2 Spike Total Immunoglobulin (Ig) and IgG-specific assays, and a semi-quantitative test for anti-SARS-CoV-2 Spike protein IgG were measured in 241 (17.2%) transplant candidates and 1163 (82.8%) transplant recipients; 55.2% of whom were non-Hispanic White and 44.8% identified as another race. Transplant recipients were a median (IQR) of 3.2 (1.1, 6.8) years from transplantation. Response differed by transplant status: 96.0% versus 43.2% by the anti-SARS-CoV-2 Total Ig (candidates vs. recipients, respectively), 93.5% versus 11.6% by the anti-SARS-CoV-2 IgG assay, and 91.9% versus 30.1% by anti-spike titers after two doses of vaccine. Multivariable analysis revealed candidates had higher likelihood of response versus recipients (odds ratio [OR], 14.6; 95 %CI 2.19, 98.11; P = .02). A slightly lower response was demonstrated in older patients (OR .96; 95 %CI .94, .99; P = .002), patients taking antimetabolites (OR, .21; 95% CI .08, .51; P = .001). Vaccination prior to transplantation should be encouraged.
(© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje